1. MAPK/ERK Pathway Stem Cell/Wnt Apoptosis
  2. ERK Caspase
  3. EF24

EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.

For research use only. We do not sell to patients.

EF24 Chemical Structure

EF24 Chemical Structure

CAS No. : 342808-40-6

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE EF24

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK[1][2].

Cellular Effect
Cell Line Type Value Description References
518A2 IC50
1.8 μM
Compound: 2; EF24
Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay
Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay
[PMID: 28774574]
A2780 IC50
0.5 μM
Compound: EF24
Cell viability of human cisplatin-sensitive human A2780 cells after 24 hrs by MTT assay
Cell viability of human cisplatin-sensitive human A2780 cells after 24 hrs by MTT assay
[PMID: 17684018]
A2780 IC50
0.65 μM
Compound: EF24
Cell viability of cisplatin-resistant human A2780 cells after 24 hrs by MTT assay
Cell viability of cisplatin-resistant human A2780 cells after 24 hrs by MTT assay
[PMID: 17684018]
A549 IC50
2.4 μM
Compound: EF24
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 29655083]
A549 IC50
2.8 μM
Compound: A1; EF24
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
[PMID: 29351887]
A549 IC50
7.1 μM
Compound: EF24
Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay
[PMID: 27886548]
CHO IC50
4.6 μM
Compound: EF24
Cell viability of CHO cells after 24 hrs by MTT assay
Cell viability of CHO cells after 24 hrs by MTT assay
[PMID: 17684018]
DLD-1 IC50
1.3 μM
Compound: 2; EF24
Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay
Cytotoxicity against human DLD1 cells after 72 hrs by MTT assay
[PMID: 28774574]
HCT-116 IC50
1.5 μM
Compound: 2; EF24
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
[PMID: 28774574]
HEK293 CC50
3.58 μM
Compound: 33
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis
[PMID: 36608774]
HeLa 229 IC50
1.9 μM
Compound: A1; EF24
Antiproliferative activity against human HeLa 229 cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa 229 cells after 72 hrs by MTT assay
[PMID: 29351887]
HepG2 IC50
3.33 μM
Compound: EF24
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 30771605]
HT-29 IC50
1.6 μM
Compound: 2; EF24
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 28774574]
L02 IC50
10.2 μM
Compound: EF24
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 30771605]
L02 IC50
5.1 μM
Compound: EF24
Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 29655083]
L02 IC50
5.8 μM
Compound: EF24
Antiproliferative activity against human HL7702 cells by MTT assay
Antiproliferative activity against human HL7702 cells by MTT assay
[PMID: 31336310]
Lewis lung carcinoma cell line IC50
8.4 μM
Compound: EF24
Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay
[PMID: 27886548]
MGC-803 IC50
2 μM
Compound: A1; EF24
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
[PMID: 29351887]
NB-4 IC50
0.29 μM
Compound: 42
Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay
[PMID: 24960549]
NCI-H1650 IC50
1.7 μM
Compound: EF24
Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 29655083]
NCI-H1650 IC50
14.6 μM
Compound: EF24
Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay
Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay
[PMID: 27886548]
NCI-H1975 IC50
1.3 μM
Compound: EF24
Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 29655083]
NCI-H441 IC50
44 μM
Compound: 1
Antiproliferative activity against human H441 cells assessed as decrease of hexosaminidase activity after 24 hrs
Antiproliferative activity against human H441 cells assessed as decrease of hexosaminidase activity after 24 hrs
[PMID: 20638855]
NCI-H460 IC50
1.2 μM
Compound: EF24
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 29655083]
NCI-H460 IC50
6 μM
Compound: EF24
Antiproliferative activity against human H460 cells by MTT assay
Antiproliferative activity against human H460 cells by MTT assay
[PMID: 31336310]
PANC-1 IC50
1.5 μM
Compound: 2; EF24
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
[PMID: 28774574]
QGY-7703 IC50
4.97 μM
Compound: EF24
Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 30771605]
SGC-7901 IC50
1 μM
Compound: A1; EF24
Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
[PMID: 29351887]
SGC-7901 IC50
6.5 μM
Compound: EF24
Antiproliferative activity against human SGC7901 cells by MTT assay
Antiproliferative activity against human SGC7901 cells by MTT assay
[PMID: 31336310]
SMMC-7721 IC50
8.8 μM
Compound: EF24
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 30771605]
U-251 IC50
4.5 μM
Compound: EF24
Antiproliferative activity against human U251 cells by MTT assay
Antiproliferative activity against human U251 cells by MTT assay
[PMID: 31336310]
U-87MG ATCC IC50
1.4 μM
Compound: 2; EF24
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
[PMID: 28774574]
Molecular Weight

311.33

Formula

C19H15F2NO

CAS No.
Appearance

Solid

Color

White to yellow

SMILES

O=C1/C(CNC/C1=C\C2=C(C=CC=C2)F)=C/C3=C(C=CC=C3)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (160.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2120 mL 16.0601 mL 32.1203 mL
5 mM 0.6424 mL 3.2120 mL 6.4241 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (8.03 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (8.03 mM); Suspended solution; Need ultrasonic

    This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.2120 mL 16.0601 mL 32.1203 mL 80.3006 mL
5 mM 0.6424 mL 3.2120 mL 6.4241 mL 16.0601 mL
10 mM 0.3212 mL 1.6060 mL 3.2120 mL 8.0301 mL
15 mM 0.2141 mL 1.0707 mL 2.1414 mL 5.3534 mL
20 mM 0.1606 mL 0.8030 mL 1.6060 mL 4.0150 mL
25 mM 0.1285 mL 0.6424 mL 1.2848 mL 3.2120 mL
30 mM 0.1071 mL 0.5353 mL 1.0707 mL 2.6767 mL
40 mM 0.0803 mL 0.4015 mL 0.8030 mL 2.0075 mL
50 mM 0.0642 mL 0.3212 mL 0.6424 mL 1.6060 mL
60 mM 0.0535 mL 0.2677 mL 0.5353 mL 1.3383 mL
80 mM 0.0402 mL 0.2008 mL 0.4015 mL 1.0038 mL
100 mM 0.0321 mL 0.1606 mL 0.3212 mL 0.8030 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
EF24
Cat. No.:
HY-119272
Quantity:
MCE Japan Authorized Agent: